Virtual tES Device Treatment for Parkinson's Disease Motor Symptoms

This study is testing a new, non-invasive device called Sphere V3.0 to see if it can help improve movement problems in people with Parkinson's disease. The device uses gentle electrical signals applied to the scalp. You might be able to join if you are 18-80 years old, have a confirmed Parkinson's diagnosis (Hoehn & Yahr stages 1-4), and have stable medications. The main goal is to see if the device improves your motor symptoms, measured by a standard rating scale (MDS-UPDRS Part III Motor Scores) after 3 weeks of treatment. The study is currently unclear on its recruitment status.

Study design
This is an interventional study with a planned enrollment of 30 participants. It is conducted virtually.
What's involved
You would use the device at home for 13 minutes each weekday (Monday through Friday) for 3 weeks. The entire study lasts 6 weeks, with virtual assessments and video recordings of your movements.
Compensation
Not stated in the trial record.
Follow-up
You will be monitored for 3 weeks after the treatment period ends.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07182058

Virtual tES Device Treatment for Parkinson's Disease Motor Symptoms

Recruiting
PHASE1Ages 18–80InterventionalTreatment
U: The Mind Company
~30 participants
Updated 2026-01-27 on ClinicalTrials.gov
What's tested:Transcranial Electrical Stimulation Device

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in MDS-UPDRS Part III Motor Scores
Measured over Baseline to Week 3 (end of treatment)
PARKINSON DISEASE (Disorder)

NCT07182058

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • U LLC Headquarters

    Cleveland, Ohiostudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Adults 18-80 years with confirmed diagnosis of Parkinson's Disease
Hoehn \& Yahr stages 1-4
Stable medication regimen for 4+ weeks prior to enrollment
Reliable internet access and telehealth capability
Ability to provide informed consent
Willingness to comply with treatment protocols and follow-up procedures

Exclusion

Metallic head/neck implants (excluding dental fillings)
Pregnancy or nursing status
Severe skin conditions at electrode placement sites
History of epilepsy or seizures (unless technology specifically indicated)
Recent stroke or traumatic brain injury (within 6 months)
Severe cognitive impairment preventing treatment understanding
Any neurological disorders contraindicating transcranial electrical stimulation
Current participation in other clinical trials
Inability to commit to full treatment and follow-up schedule
  • Change in MDS-UPDRS Part III Motor ScoresBaseline to Week 3 (end of treatment)

    Change from baseline to end of treatment in Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III motor examination scores. The MDS-UPDRS Part III assesses motor signs of Parkinson's disease including tremor, rigidity, bradykinesia, and postural instability. Scores range from 0-132 with higher scores indicating worse motor function. All assessments conducted by qualified medical personnel including physicians, certified research coordinators, or trained clinical research assistants under physician supervision.